Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 10

1577P - Indoor radon in patients with lung cancer in Spain: Preliminary data from the MIRROR study

Date

14 Sep 2024

Session

Poster session 10

Topics

Primary Prevention;  Cancer Epidemiology

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Marta Garcia De Herreros

Citation

Annals of Oncology (2024) 35 (suppl_2): S937-S961. 10.1016/annonc/annonc1606

Authors

M. Garcia De Herreros1, M.B. Bernabeu Aracil2, M. Ferriol-Galmés3, F.J. Muñoz i Carrillo1, S. Medina Valdivieso4, H. Arasanz5, S. Vazquez Estevez6, S. Catort Tort7, L.A. Leon Mateos8, R. Alvarez Cabellos9, P. Cruz Castellanos10, G. Rubio Romero11, L. Aguilar Corominas12, L. Alcolea Contreras2, A. Arcocha1, M. Jiménez2, J.C. Laguna Montes1, C. Teixido13, R. López Castro14, L. Mezquita1

Author affiliations

  • 1 Medical Oncology Department, Hospital Clinic y Provincial de Barcelona, 08036 - Barcelona/ES
  • 2 Translational Genomics And Targeted Therapies In Solid Tumours, IDIBAPS - Fundació de Recerca Clinic Barcelona - Institut d'Investigacions Biomediques August Pi i Sunyer, 08036 - Barcelona/ES
  • 3 Department Of Computer Architecture, Universitat Politècnica de Catalunya · Barcelona Tech - UPC, 08034 - Barcelona/ES
  • 4 Medical Oncology Department, Complejo Asistencial Universitario de León - Hospital de León, 24071 - León/ES
  • 5 Medical Oncology Department, Complejo Hospitalario de Navarra - Royal Navarre Hospital, 31008 - Pamplona/ES
  • 6 Medical Oncology Department, Hospital Xeral Calde of Lugo, 27004 - Lugo/ES
  • 7 Medical Oncology Department, Hospital de Sant Joan de Déu - Althaia, Xarxa Assistencial Universitària de Manresa, 08243 - Manresa/ES
  • 8 Medical Oncology Department, CHUS - Complejo Hospitalario Universitario de Santiago de Compostela SERGAS, 15706 - Santiago de Compostela/ES
  • 9 Medical Oncology Department, Hospital Virgen de la Salud, 49004 - Toledo/ES
  • 10 Medical Oncology Department, Hospital Universitario de Cuidad Real, 13002 - Ciudad Real/ES
  • 11 Medical Oncology Department, Hospital Infanta Sofía, 28703 - Madrid/ES
  • 12 Faculty Of Medicine, University of Barcelona, 08036 - Barcelona/ES
  • 13 Pathology Department, Hospital Clinic y Provincial de Barcelona, 08036 - Barcelona/ES
  • 14 Radiation And Medical Oncology Department, Hospital Clinico Universitario de Valladolid, 47003 - Valladolid/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1577P

Background

Indoor radon (Rn) is one of the leading causes of lung cancer (LC) in non-smokers, and the 2nd one in smokers. However, it remains unknown in Spain. We studied indoor Rn in a large cohort of patients (pts) with non-small cell LC (NSCLC) in Spain.

Methods

Prospective multicentric study of pts with NSCLC enrolled in 12 hospitals (6 regions) in Spain from Jan. 2021 to date. Each pt received 1 or 2 alpha-track detectors to measure Rn for ≥3 months in their home, and a detailed questionnaire, with demographics, smoking, other exposures, etc. Clinical/Tumor data were prospectively collected and optional tissue sample for translational research.

Results

Out of 613 pts enrolled to date, we report here data of 209: 58,8% male, 77,2% smokers, with median age of 64; 72 (34,4%) with primary school education. One third had advanced stage. Adenocarcinoma was the predominant histology (83,2%). Molecular profile was known for 190 (90,1%) being EGFR the most common alteration (13,8%). Most of pts lived in flat (68%), followed by detached house (25%); 24% lived in basement, ground floor; 64,1% living there ≥ 20 years. Before participating in this study, most of the pts (55.6%) were not aware of Rn. Among those who were familiar with Rn, television was the main source of information (40.8%), followed by school (29%). After the study, 88.9% request more information about Rn. Overall, the media Rn was 36 Bq/m3 (10-600); higher Rn was observed in ground floor (75 vs. 34 Bq/m3 in the rest, p=0.012). Forty-two pts (20.1%) had Rn ≥100Bq/m3 and 15 (7.2%) ≥ 200Bq/m3. Highest Rn was observed in Galicia, with median of 156 Bq/m3, vs. Catalonia, with 17 Bq/m3 (p<0.001). Among pts living in their homes for ≥ 20y (n=142), the median Rn was 34 Bq/m3 (10-600). Higher Rn was observed in ground floors (55.6% of those with ≥200 Bq/m3). 25 pts (17.6%) had Rn median ≥100 Bq/m3, 8 (5.6%) ≥200 Bq/m3. In this preliminary cohort, no differences were observed in Rn levels (median) by sex, smoking habits or histology.

Conclusions

Most pts in this study were unaware of Rn, a prevalent risk factor for LC in Spain. The measurement of indoor Rn is feasible, with 20.1% of pts homes with ≥100Bq/m3 and 7.2% ≥200 Bq/m3, providing valuable data for cancer prevention. This study is still ongoing to study the Rn-associated profile in a larger cohort of pts.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Project FIS PI21/01653, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union.

Disclosure

M. Garcia De Herreros: Financial Interests, Personal, Invited Speaker: NOVARTIS, IPSEN. H. Arasanz: Financial Interests, Personal, Invited Speaker: Takeda; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Other, Clinical Trial coordination: Ferrer Farma; Financial Interests, Personal, Other, Travelling/accommodation expenses: Angelini, BMS, MSD, Roche, Takeda. S. Vazquez Estevez: Financial Interests, Personal, Advisory Board: BMS. S. Catort Tort: Financial Interests, Personal, Advisory Board: AstraZeneca, Roche, Pfizer. L.A. Leon Mateos: Financial Interests, Personal, Advisory Board: AstraZeneca, Pfizer, Bristol, Merck, Amgen, Takeda, Janssen. C. Teixido: Financial Interests, Personal, Invited Speaker: AstraZeneca, Merck Sharp & Dohme, Roche Farma, Diaceutics, Pfizer; Financial Interests, Personal, Advisory Board: AstraZeneca, Novartis; Financial Interests, Institutional, Research Grant: Novartis, AstraZeneca. R. López Castro: Financial Interests, Personal, Advisory Board: AstraZeneca, Roche, Novartis, Amgen, Pierre Fabre. L. Mezquita: Financial Interests, Personal, Advisory Board: Takeda, Roche, AstraZeneca, MSD, Janssen; Financial Interests, Personal, Invited Speaker: Takeda, Roche, BMS, AstraZeneca, Janssen; Financial Interests, Personal, Research Grant, SEOM Beca Retorno 2019: BI; Financial Interests, Personal, Research Grant, ESMO TR Research Fellowship 2019: BMS; Financial Interests, Institutional, Research Grant, COVID research Grant: Amgen; Financial Interests, Institutional, Coordinating PI, Cover cost of molecular test: Inivata; Financial Interests, Institutional, Coordinating PI: GILEAD; Financial Interests, Institutional, Coordinating PI, Beca SEOM Grupo Emergente 2022: AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.